The US Food and Drug Administration (FDA) has approved Boston Scientific's next-generation drug-eluting stent (DES) technology - Promus Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System.
The Promus Element Stent is made with a proprietary platinum chromium (PtCr) alloy and everolimus drug.
The PtCr alloy is designed specifically for coronary stenting, which enables thinner struts and enhanced visibility and the Promus design provides a more conformable stent with less recoil and higher radial strength.
The Promus Element Stent includes an advanced low-profile delivery system featuring a dual-layer balloon and Bi-Segment inner lumen catheter designed to facilitate precise stent delivery across challenging lesions.
The company claims the everolimus drug and fluorinated copolymer stent coating which have been studied in multiple randomized clinical trials showed long-term safety and efficacy.